Technical Analysis for PBYI - Puma Biotechnology Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 0.61% | |
| Pocket Pivot | Bullish Swing Setup | 0.61% | |
| Volume Surge | Other | 0.61% | |
| Wide Bands | Range Expansion | 0.61% | |
| Up 3 Days in a Row | Strength | 0.61% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 7 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Fell Below 10 DMA | about 9 hours ago |
| 10 DMA Support | about 10 hours ago |
| Down 5% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/01/2024
Puma Biotechnology Inc Description
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Organic Compounds Breast Cancer Chemical Compounds Non Small Cell Lung Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Protein Kinase Inhibitor Signal Transduction Tyrosine Kinase Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Chloroarenes Her2 Her2/Neu Pyridines Advanced Breast Cancer Advanced Cancer Nitriles
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.73 |
| 52 Week Low | 2.13 |
| Average Volume | 490,584 |
| 200-Day Moving Average | 4.26 |
| 50-Day Moving Average | 4.09 |
| 20-Day Moving Average | 3.31 |
| 10-Day Moving Average | 3.11 |
| Average True Range | 0.24 |
| RSI (14) | 40.83 |
| ADX | 40.02 |
| +DI | 14.59 |
| -DI | 23.38 |
| Chandelier Exit (Long, 3 ATRs) | 3.35 |
| Chandelier Exit (Short, 3 ATRs) | 3.54 |
| Upper Bollinger Bands | 3.82 |
| Lower Bollinger Band | 2.80 |
| Percent B (%b) | 0.47 |
| BandWidth | 31.01 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.33 |
| MACD Histogram | 0.0592 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.67 | ||||
| Resistance 3 (R3) | 3.63 | 3.46 | 3.61 | ||
| Resistance 2 (R2) | 3.46 | 3.36 | 3.48 | 3.58 | |
| Resistance 1 (R1) | 3.37 | 3.30 | 3.42 | 3.41 | 3.56 |
| Pivot Point | 3.20 | 3.20 | 3.22 | 3.22 | 3.20 |
| Support 1 (S1) | 3.11 | 3.10 | 3.16 | 3.15 | 3.00 |
| Support 2 (S2) | 2.94 | 3.04 | 2.96 | 2.98 | |
| Support 3 (S3) | 2.85 | 2.94 | 2.96 | ||
| Support 4 (S4) | 2.89 |
